As of January 19, 2026, there has been “no official, nationwide recall of prazosin” issued by the U.S. Food and Drug Administration (FDA) or major manufacturers. Prazosin remains available in the United States, with “no FDA-designated Class I, Class II, or Class III recalls” reported in late 2025 or early 2026. FDA monitoring systems show no widespread safety, contamination, labeling, or manufacturing problems requiring removal from pharmacies.

Prazosin, originally sold as Minipress, is an alpha-1 blocker approved in the 1970s. It is commonly prescribed for high blood pressure and benign prostatic hyperplasia (BPH). It is also widely used off-label to treat PTSD-related nightmares. The medication has a long safety record and is produced by several generic manufacturers under regular FDA oversight.

Large recalls are categorized by severity. Class I involves a reasonable probability of serious harm or death. Class II may cause temporary or reversible effects. Class III involves minor regulatory violations unlikely to cause harm. As of early 2026, prazosin does not appear in any of these categories. There have also been no manufacturer-wide recalls from major producers.

While no national recall exists, small lot-level issues can happen with any drug. These may involve minor labeling or packaging problems and are often handled quietly at the pharmacy or distributor level without a public alert. Such isolated cases do not equal a nationwide recall.

Confusion may stem from past recalls of other blood pressure drugs due to nitrosamine contamination, but prazosin was not involved. Patients concerned about safety can check their prescription label for lot details and consult the FDA recall database or their pharmacist. Current evidence confirms prazosin remains approved, regulated, and safe for continued use as prescribed.